Edwards Lifesciences Corporation Company Profile (NYSE:EW)

About Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation logoEdwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:EW
  • CUSIP: 28176E10
  • Web: www.edwards.com
Capitalization:
  • Market Cap: $23.88408 billion
  • Outstanding Shares: 211,158,000
Average Prices:
  • 50 Day Moving Avg: $116.42
  • 200 Day Moving Avg: $106.02
  • 52 Week Range: $81.12 - $121.75
P/E:
  • Trailing P/E Ratio: 34.31
  • Foreward P/E Ratio: 27.12
  • P/E Growth: 1.88
Sales & Book Value:
  • Annual Revenue: $3.23 billion
  • Price / Sales: 7.39
  • Book Value: $13.93 per share
  • Price / Book: 8.12
Profitability:
  • EBIDTA: $1.05 billion
  • Net Margins: 22.16%
  • Return on Equity: 27.17%
  • Return on Assets: 15.91%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 4.06%
  • Quick Ratio: 3.19%
Misc:
  • Average Volume: 1.15 million shs.
  • Beta: 0.63
  • Short Ratio: 1.54
 

Frequently Asked Questions for Edwards Lifesciences Corporation (NYSE:EW)

What is Edwards Lifesciences Corporation's stock symbol?

Edwards Lifesciences Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences Corporation's stock split? How did Edwards Lifesciences Corporation's stock split work?

Edwards Lifesciences Corporation's stock split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were issued to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences Corporation stock prior to the split would have 200 shares after the split.

How were Edwards Lifesciences Corporation's earnings last quarter?

Edwards Lifesciences Corporation (NYSE:EW) announced its quarterly earnings results on Wednesday, July, 26th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.88 by $0.20. The firm earned $842 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.76 earnings per share. View Edwards Lifesciences Corporation's Earnings History.

When will Edwards Lifesciences Corporation make its next earnings announcement?

Edwards Lifesciences Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Edwards Lifesciences Corporation.

What guidance has Edwards Lifesciences Corporation issued on next quarter's earnings?

Edwards Lifesciences Corporation updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $3.65-3.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.54. The company issued revenue guidance of $, compared to the consensus revenue estimate of $3.35 billion.Edwards Lifesciences Corporation also updated its Q3 guidance to $0.80-0.90 EPS.

Where is Edwards Lifesciences Corporation's stock going? Where will Edwards Lifesciences Corporation's stock price be in 2017?

19 brokers have issued twelve-month price targets for Edwards Lifesciences Corporation's shares. Their forecasts range from $14.00 to $155.00. On average, they expect Edwards Lifesciences Corporation's stock price to reach $119.39 in the next twelve months. View Analyst Ratings for Edwards Lifesciences Corporation.

What are analysts saying about Edwards Lifesciences Corporation stock?

Here are some recent quotes from research analysts about Edwards Lifesciences Corporation stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Edwards Lifesciences has outperformed the Zacks categorized Medical - Instruments industry. We believe several recent FDA approvals received by the company including its SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting the investors’ confidence over the stock. Also, Edwards Lifesciences’ long-term growth strategy buoys optimism. The company’s focus on bulding its pipeline to strengthen its foothold across all its operating businesses is also encouraging. However, higher operating expenses continue to be a woe. The stock’s valuation also remains stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (7/18/2017)
  • 2. Cowen and Company analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)

Who are some of Edwards Lifesciences Corporation's key competitors?

Who are Edwards Lifesciences Corporation's key executives?

Edwards Lifesciences Corporation's management team includes the folowing people:

  • Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
  • Scott B. Ullem, Chief Financial Officer, Corporate Vice President
  • Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
  • Catherine M. Szyman, Corporate Vice President- Critical Care
  • Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
  • Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
  • Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
  • Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
  • Kieran T. Gallahue, Independent Director
  • Leslie Stone Heisz, Independent Director

Who owns Edwards Lifesciences Corporation stock?

Edwards Lifesciences Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.83%), BlackRock Inc. (6.68%), State Street Corp (4.31%), Alliancebernstein L.P. (2.82%), Bank of New York Mellon Corp (2.52%) and Ameriprise Financial Inc. (2.06%). Company insiders that own Edwards Lifesciences Corporation stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences Corporation.

Who sold Edwards Lifesciences Corporation stock? Who is selling Edwards Lifesciences Corporation stock?

Edwards Lifesciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., FMR LLC, Fred Alger Management Inc., Voya Investment Management LLC, Marshall Wace North America L.P., Winslow Capital Management LLC, Alliancebernstein L.P. and State Street Corp. Company insiders that have sold Edwards Lifesciences Corporation stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Huimin Wang, Larry L Wood, Michael A Mussallem and Patrick B Verguet. View Insider Buying and Selling for Edwards Lifesciences Corporation.

Who bought Edwards Lifesciences Corporation stock? Who is buying Edwards Lifesciences Corporation stock?

Edwards Lifesciences Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Egerton Capital UK LLP, Koch Industries Inc., Artisan Partners Limited Partnership, Harbour Capital Advisors LLC, Vanguard Group Inc., Wells Fargo & Company MN and Delta Lloyd Asset Management N.V.. Company insiders that have bought Edwards Lifesciences Corporation stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences Corporation.

How do I buy Edwards Lifesciences Corporation stock?

Shares of Edwards Lifesciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences Corporation's stock price today?

One share of Edwards Lifesciences Corporation stock can currently be purchased for approximately $113.11.


MarketBeat Community Rating for Edwards Lifesciences Corporation (NYSE EW)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  777 (Vote Outperform)
Underperform Votes:  527 (Vote Underperform)
Total Votes:  1,304
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Edwards Lifesciences Corporation (NYSE:EW) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $119.39 (5.55% upside)

Analysts' Ratings History for Edwards Lifesciences Corporation (NYSE:EW)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/30/2017Canaccord GenuityReiterated RatingBuy$150.00 -> $155.00LowView Rating Details
7/28/2017Royal Bank Of CanadaReiterated RatingBuy$130.00LowView Rating Details
7/27/2017Cowen and CompanyReiterated RatingOutperform$130.00 -> $135.00LowView Rating Details
7/27/2017Barclays PLCBoost Price TargetEqual Weight$108.00 -> $120.00LowView Rating Details
7/27/2017Stifel NicolausReiterated RatingBuy -> Buy$118.00 -> $130.00HighView Rating Details
7/27/2017Bank of America CorporationBoost Price TargetPositive -> Buy$140.00 -> $150.00HighView Rating Details
7/27/2017Jefferies Group LLCBoost Price TargetBuy$115.00 -> $132.00HighView Rating Details
7/17/2017SunTrust Banks, Inc.Boost Price TargetBuy$14.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageConviction-Buy$138.00LowView Rating Details
3/27/2017Evercore ISIUpgradeIn-Line -> Outperform$98.50 -> $110.00LowView Rating Details
3/20/2017Northland SecuritiesSet Price TargetBuy$105.00LowView Rating Details
2/8/2017Credit Suisse GroupSet Price TargetBuy$120.00N/AView Rating Details
2/5/2017Deutsche Bank AGReiterated RatingHold$100.00N/AView Rating Details
2/2/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
1/3/2017GuggenheimUpgradeNeutral -> Buy$120.00N/AView Rating Details
12/10/2016JMP SecuritiesReiterated RatingEqual Weight$130.00N/AView Rating Details
12/1/2016J P Morgan Chase & CoSet Price TargetBuy$120.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/19/2016Morgan StanleyReiterated RatingBuy$140.00N/AView Rating Details
7/27/2016Citigroup Inc.Boost Price TargetSell$86.00 -> $94.00N/AView Rating Details
7/27/2016BMO Capital MarketsReiterated RatingBuy$120.00N/AView Rating Details
6/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$123.00N/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$101.00N/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$90.00 -> $92.00N/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for Edwards Lifesciences Corporation (NYSE:EW)
Earnings by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Earnings History by Quarter for Edwards Lifesciences Corporation (NYSE EW)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/23/2017$0.83N/AView Earnings Details
7/26/2017Q2 2017$0.88$1.08$839.16 million$842.00 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.82$0.94$776.51 million$883.50 millionViewN/AView Earnings Details
2/1/2017Q416$0.72$0.75$760.85 million$767.70 millionViewN/AView Earnings Details
10/25/2016Q316$0.68$0.68$749.14 million$739.40 millionViewN/AView Earnings Details
7/26/2016Q216$0.70$0.76$724.26 million$759.30 millionViewN/AView Earnings Details
4/26/2016Q116$0.66$0.71$664.53 million$697.30 millionViewN/AView Earnings Details
2/2/2016Q415$0.62$0.63$647.44 million$671.10 millionViewN/AView Earnings Details
10/26/2015Q315$0.98$1.07$598.29 million$615.00 millionViewN/AView Earnings Details
7/28/2015Q215$1.05$1.13$604.97 million$616.80 millionViewN/AView Earnings Details
4/23/2015Q115$1.04$1.12$585.16 million$590.30 millionViewN/AView Earnings Details
2/3/2015Q414$0.95$1.06$610.50 million$618.00 millionViewListenView Earnings Details
10/23/2014Q314$0.72$0.80$546.10 million$607.40 millionViewListenView Earnings Details
7/29/2014Q214$0.77$0.88$545.10 million$547.00 millionViewListenView Earnings Details
4/24/2014Q114$0.69$0.76$523.10 million$522.40 millionViewListenView Earnings Details
2/3/2014Q413$0.82$0.91$533.82 million$536.00 millionViewN/AView Earnings Details
10/28/2013Q313$0.66$0.68$490.96 million$496.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013$0.76$0.82$514.59 million$517.20 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.76$0.72$518.69 million$496.70 millionViewN/AView Earnings Details
2/4/2013Q4 2012$0.77$0.77$499.46 million$510.50 millionViewN/AView Earnings Details
10/19/2012$0.56$0.58ViewN/AView Earnings Details
7/24/2012$0.66$0.67ViewN/AView Earnings Details
2/2/2012$0.59$0.62ViewN/AView Earnings Details
10/19/2011$0.39$0.38ViewN/AView Earnings Details
7/21/2011$0.50$0.49ViewN/AView Earnings Details
4/20/2011$0.42$0.51ViewN/AView Earnings Details
2/2/2011$0.53$0.55ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edwards Lifesciences Corporation (NYSE:EW)
2017 EPS Consensus Estimate: $3.44
2018 EPS Consensus Estimate: $4.05
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$0.82$0.85$0.84
Q2 20174$0.87$0.89$0.88
Q3 20174$0.79$0.86$0.84
Q4 20174$0.88$0.92$0.89
Q1 20183$0.95$1.10$1.03
Q2 20183$1.04$1.09$1.06
Q3 20183$0.92$0.98$0.95
Q4 20183$0.96$1.05$1.02
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edwards Lifesciences Corporation (NYSE:EW)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Edwards Lifesciences Corporation (NYSE:EW)
Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 84.67%
Insider Trades by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Insider Trades by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2017Michael A. MussallemCEOSell32,900$115.99$3,816,071.00View SEC Filing  
8/4/2017Donald E. Bobo, Jr.VPSell25,000$116.00$2,900,000.00View SEC Filing  
7/31/2017Catherine M. SzymanVPSell4,681$115.78$541,966.18View SEC Filing  
7/31/2017Michael A. MussallemCEOSell32,900$114.80$3,776,920.00View SEC Filing  
7/28/2017Donald E. Bobo, Jr.VPSell5,300$114.68$607,804.00View SEC Filing  
6/29/2017Donald E. Bobo, Jr.VPSell5,600$117.15$656,040.00View SEC Filing  
6/7/2017Michael A. MussallemCEOSell32,900$118.05$3,883,845.00View SEC Filing  
5/31/2017Patrick B. VerguetVPSell10,000$114.88$1,148,800.00View SEC Filing  
5/19/2017Dylan SidooDirectorBuy25,000$0.11$2,750.00
5/19/2017Patrick B. VerguetVPSell22,631$113.16$2,560,923.96View SEC Filing  
5/15/2017Patrick B. VerguetVPSell11,500$111.64$1,283,860.00View SEC Filing  
5/8/2017Donald E. Bobo, Jr.VPSell19,100$110.34$2,107,494.00View SEC Filing  
5/4/2017Donald E. Bobo, Jr.VPSell34,120$109.98$3,752,517.60View SEC Filing  
5/3/2017Michael A. MussallemCEOSell49,100$109.71$5,386,761.00View SEC Filing  
4/28/2017Michael A. MussallemCEOSell49,100$109.78$5,390,198.00View SEC Filing  
4/27/2017Bernard J. ZovighianVPSell18,050$109.21$1,971,240.50View SEC Filing  
4/5/2017Donald E. Bobo, Jr.VPSell13,720$93.58$1,283,917.60View SEC Filing  
3/30/2017Patrick B. VerguetVPSell24,000$93.90$2,253,600.00View SEC Filing  
3/6/2017Donald E. Bobo, Jr.VPSell13,720$90.01$1,234,937.20View SEC Filing  
2/16/2017Michael A. MussallemCEOSell49,100$89.63$4,400,833.00View SEC Filing  
2/3/2017Kieran GallahueDirectorBuy3,000$90.10$270,300.00View SEC Filing  
1/13/2017Michael A. MussallemCEOSell49,100$97.08$4,766,628.00View SEC Filing  
1/12/2017Donald E. Bobo, Jr.VPSell13,720$97.47$1,337,288.40View SEC Filing  
1/12/2017Dylan SidooDirectorBuy30,000$0.13$3,900.00
1/11/2017Dylan SidooDirectorBuy20,000$0.13$2,600.00
12/19/2016Michael A. MussallemCEOSell49,100$91.96$4,515,236.00View SEC Filing  
12/5/2016Huimin WangVPSell13,650$83.53$1,140,184.50View SEC Filing  
12/1/2016Larry L. WoodVPSell13,258$81.85$1,085,167.30View SEC Filing  
11/30/2016Catherine M. SzymanVPBuy12,870$83.43$1,073,744.10View SEC Filing  
11/29/2016Kieran GallahueDirectorBuy3,000$84.63$253,890.00View SEC Filing  
11/22/2016Michael A. MussallemCEOSell49,100$84.67$4,157,297.00View SEC Filing  
11/7/2016Huimin WangVPSell13,650$91.29$1,246,108.50View SEC Filing  
11/2/2016Donald E. Bobo, Jr.VPSell15,000$90.13$1,351,950.00View SEC Filing  
11/1/2016Larry L. WoodVPSell13,257$93.27$1,236,480.39View SEC Filing  
10/27/2016Michael A. MussallemCEOSell49,100$92.77$4,555,007.00View SEC Filing  
10/5/2016Huimin WangVPSell13,650$120.04$1,638,546.00View SEC Filing  
10/3/2016Larry L. WoodVPSell13,257$119.27$1,581,162.39View SEC Filing  
9/6/2016Huimin WangVPSell13,650$115.72$1,579,578.00View SEC Filing  
9/2/2016Donald E. Bobo, Jr.VPSell18,000$115.78$2,084,040.00View SEC Filing  
8/26/2016Patrick B. VerguetVPSell5,000$114.88$574,400.00View SEC Filing  
8/24/2016Patrick B. VerguetVPSell5,000$116.81$584,050.00View SEC Filing  
8/23/2016Patrick B. VerguetVPSell10,092$117.53$1,186,112.76View SEC Filing  
8/11/2016Michael A. MussallemCEOSell49,100$114.01$5,597,891.00View SEC Filing  
8/10/2016John T. CardisDirectorSell5,000$113.21$566,050.00View SEC Filing  
8/9/2016Patrick B. VerguetVPSell10,000$113.48$1,134,800.00View SEC Filing  
8/5/2016Huimin WangVPSell13,650$113.03$1,542,859.50View SEC Filing  
8/1/2016Larry L. WoodVPSell13,257$114.24$1,514,479.68View SEC Filing  
8/1/2016Schack Wesley W. VonDirectorSell6,000$113.98$683,880.00View SEC Filing  
7/29/2016Robert W.A. SellersVPSell10,000$114.33$1,143,300.00View SEC Filing  
7/28/2016Michael A. MussallemCEOSell49,100$113.31$5,563,521.00View SEC Filing  
7/5/2016Huimin WangVPSell13,650$98.44$1,343,706.00View SEC Filing  
7/1/2016Larry L. WoodVPSell13,257$98.79$1,309,659.03View SEC Filing  
6/8/2016Michael A MussallemCEOSell49,100$102.75$5,045,025.00View SEC Filing  
6/6/2016Huimin WangVPSell13,650$101.34$1,383,291.00View SEC Filing  
6/3/2016Larry L WoodVPSell13,257$101.38$1,343,994.66View SEC Filing  
5/31/2016Donald E Bobo JrVPSell18,000$99.04$1,782,720.00View SEC Filing  
5/24/2016Steven R LorangerDirectorBuy5,000$101.07$505,350.00View SEC Filing  
5/18/2016Patrick B VerguetVPSell13,000$102.75$1,335,750.00View SEC Filing  
5/17/2016Patrick B VerguetVPSell5,000$105.00$525,000.00View SEC Filing  
5/16/2016Patrick B VerguetVPSell3,000$104.62$313,860.00View SEC Filing  
5/5/2016Huimin WangVPSell13,650$103.36$1,410,864.00View SEC Filing  
5/5/2016Michael A MussallemCEOSell59,000$104.12$6,143,080.00View SEC Filing  
5/2/2016Patrick B VerguetVPSell7,000$106.86$748,020.00View SEC Filing  
4/29/2016Michael A MussallemCEOSell59,000$106.13$6,261,670.00View SEC Filing  
4/5/2016Huimin WangVPSell13,650$103.97$1,419,190.50View SEC Filing  
3/17/2016Michael A MussallemCEOSell59,000$84.39$4,979,010.00View SEC Filing  
3/7/2016Huimin WangVPSell13,650$87.17$1,189,870.50View SEC Filing  
2/18/2016Michael A. MussallemCEOSell59,000$86.94$5,129,460.00View SEC Filing  
2/18/2016Patrick B. VerguetVPSell5,000$87.00$435,000.00View SEC Filing  
2/16/2016Patrick B. VerguetVPSell8,000$81.58$652,640.00View SEC Filing  
2/5/2016Huimin WangVPSell13,650$83.46$1,139,229.00View SEC Filing  
2/4/2016Barbara J. McneilDirectorSell4,000$83.29$333,160.00View SEC Filing  
1/21/2016Patrick B. VerguetVPSell8,000$77.00$616,000.00View SEC Filing  
1/6/2016Nick DemareDirectorBuy15,000$0.08$1,200.00
1/5/2016Huimin WangVPSell13,650$78.50$1,071,525.00View SEC Filing  
1/5/2016Michael A. MussallemCEOSell59,000$79.82$4,709,380.00View SEC Filing  
12/17/2015Michael A. MussallemCEOSell59,000$81.85$4,829,150.00View SEC Filing  
12/15/2015Patrick B. VerguetVPSell8,000$80.87$646,960.00View SEC Filing  
12/4/2015Huimin WangVPSell6,880$157.96$1,086,764.80View SEC Filing  
11/27/2015Patrick B. VerguetVPSell7,500$164.50$1,233,750.00View SEC Filing  
11/23/2015Robert W.A. SellersVPSell19,200$157.13$3,016,896.00View SEC Filing  
11/17/2015Patrick B. VerguetVPSell4,000$154.50$618,000.00View SEC Filing  
11/5/2015Huimin WangVPSell6,920$156.01$1,079,589.20View SEC Filing  
11/3/2015Patrick B. VerguetVPSell4,338$158.48$687,486.24View SEC Filing  
10/30/2015Patrick B. VerguetVPSell22,000$155.09$3,411,980.00View SEC Filing  
10/29/2015Michael A MussallemCEOSell29,500$154.59$4,560,405.00View SEC Filing  
10/5/2015Huimin WangVPSell6,920$154.30$1,067,756.00View SEC Filing  
10/2/2015Patrick B. VerguetVPSell4,000$154.00$616,000.00View SEC Filing  
10/1/2015Larry L. WoodVPSell7,680$141.52$1,086,873.60View SEC Filing  
9/21/2015Michael A. MussallemCEOSell29,500$142.49$4,203,455.00View SEC Filing  
9/4/2015Huimin WangVPSell6,920$135.19$935,514.80View SEC Filing  
9/1/2015Larry L. WoodVPSell7,680$137.50$1,056,000.00View SEC Filing  
8/24/2015Michael A. MussallemCEOSell29,500$135.25$3,989,875.00View SEC Filing  
8/13/2015West Petroleum Corp. EastInsiderBuy25,000$0.12$2,875.00
7/6/2015Huimin WangVPSell6,920$143.95$996,134.00View SEC Filing  
7/1/2015Larry L WoodVPSell7,680$143.51$1,102,156.80View SEC Filing  
6/24/2015Michael A MussallemCEOSell29,500$143.71$4,239,445.00View SEC Filing  
6/5/2015Huimin WangVPSell6,920$131.39$909,218.80View SEC Filing  
6/1/2015Larry L WoodVPSell7,680$130.47$1,002,009.60View SEC Filing  
5/29/2015Patrick B VerguetVPSell9,662$131.18$1,267,461.16View SEC Filing  
5/21/2015Barbara J McneilDirectorSell2,000$132.59$265,180.00View SEC Filing  
5/19/2015Robert Marc BustinDirectorSell10,000$0.18$1,750.00
5/1/2015Larry L WoodVPSell7,680$127.12$976,281.60View SEC Filing  
4/30/2015Michael A MussallemCEOSell29,500$128.99$3,805,205.00View SEC Filing  
4/6/2015Huimin WangVPSell6,920$140.24$970,460.80View SEC Filing  
4/1/2015Larry L WoodVPSell7,680$142.06$1,091,020.80View SEC Filing  
3/31/2015Robert Marc BustinDirectorBuy15,000$0.15$2,250.00
3/26/2015Michael A MussallemCEOSell29,500$140.10$4,132,950.00View SEC Filing  
3/2/2015Larry L WoodVPSell7,680$132.62$1,018,521.60View SEC Filing  
2/6/2015Huimin WangVPSell6,920$134.79$932,746.80View SEC Filing  
1/5/2015Huimin WangVPSell6,920$126.60$876,072.00View SEC Filing  
1/5/2015Michael A MussallemCEOSell29,500$128.20$3,781,900.00View SEC Filing  
12/22/2014Michael A MussallemCEOSell29,500$133.01$3,923,795.00View SEC Filing  
11/24/2014Michael A MussallemCEOSell29,500$124.25$3,665,375.00View SEC Filing  
11/13/2014Robert W.A. SellersVPSell3,400$124.27$422,518.00View SEC Filing  
11/10/2014Patrick B VerguetVPSell5,000$123.70$618,500.00View SEC Filing  
11/7/2014Schack Wesley W VonDirectorSell3,655$123.00$449,565.00View SEC Filing  
11/5/2014Huimin WangVPSell5,600$120.26$673,456.00View SEC Filing  
10/28/2014Barbara J McneilDirectorSell1,000$117.94$117,940.00View SEC Filing  
10/28/2014Michael A MussallemCEOSell29,500$117.06$3,453,270.00View SEC Filing  
10/28/2014Patrick B VerguetVPSell15,000$117.33$1,759,950.00View SEC Filing  
10/28/2014West Petroleum Corp. EastInsiderBuy15,000$0.12$1,800.00
10/27/2014Patrick B VerguetVPSell10,000$117.00$1,170,000.00View SEC Filing  
10/27/2014West Petroleum Corp. EastInsiderBuy20,000$0.13$2,600.00
10/24/2014Donald E Bobo JrVPSell30,000$114.25$3,427,500.00View SEC Filing  
10/24/2014West Petroleum Corp. EastInsiderBuy35,000$0.14$4,725.00
10/23/2014West Petroleum Corp. EastInsiderBuy40,000$0.15$5,800.00
10/6/2014Huimin WangVPSell5,600$107.00$599,200.00View SEC Filing  
10/3/2014Donald E Bobo JrVPSell25,000$105.00$2,625,000.00View SEC Filing  
9/29/2014Michael A MussallemCEOSell29,500$102.71$3,029,945.00View SEC Filing  
9/10/2014Donald E Bobo JrVPSell25,000$100.00$2,500,000.00View SEC Filing  
9/5/2014Huimin WangVPSell5,600$98.29$550,424.00View SEC Filing  
8/27/2014Carlyn D SolomonVPSell85,200$97.85$8,336,820.00View SEC Filing  
8/27/2014Michael A MussallemCEOSell29,500$98.14$2,895,130.00View SEC Filing  
8/18/2014John T CardisDirectorSell6,000$97.92$587,520.00View SEC Filing  
8/18/2014Larry L WoodVPSell63,752$97.85$6,238,133.20View SEC Filing  
8/13/2014Patrick B VerguetVPSell7,800$95.50$744,900.00View SEC Filing  
8/5/2014Patrick B VerguetVPSell15,000$94.05$1,410,750.00View SEC Filing  
8/4/2014Patrick B VerguetVPSell5,000$93.00$465,000.00View SEC Filing  
8/1/2014Patrick B VerguetVPSell5,000$92.00$460,000.00View SEC Filing  
7/31/2014Michael A MussallemCEOSell29,500$91.98$2,713,410.00View SEC Filing  
7/31/2014Robert Alexander IngramDirectorSell12,500$90.26$1,128,250.00View SEC Filing  
7/31/2014Robert W.A. SellersVPSell8,850$91.47$809,509.50View SEC Filing  
7/30/2014Donald E Bobo JrVPSell23,270$92.00$2,140,840.00View SEC Filing  
7/7/2014Huimin WangVPSell5,600$87.79$491,624.00View SEC Filing  
6/27/2014Donald E Bobo JrVPSell25,000$87.00$2,175,000.00View SEC Filing  
6/24/2014Michael A MussallemCEOSell29,500$85.38$2,518,710.00View SEC Filing  
6/5/2014Huimin WangVPSell5,600$80.73$452,088.00View SEC Filing  
5/30/2014Barbara J McneilDirectorSell1,200$81.20$97,440.00View SEC Filing  
5/28/2014Michael A MussallemCEOSell29,500$79.33$2,340,235.00View SEC Filing  
4/14/2014Donald Bobo, Jr.VPSell25,000$82.00$2,050,000.00View SEC Filing  
4/10/2014Michael MussallemCEOSell29,500$74.71$2,203,945.00View SEC Filing  
4/7/2014Huimin WangVPSell5,600$74.03$414,568.00View SEC Filing  
3/24/2014Michael BowlinDirectorSell1,093$72.33$79,056.69View SEC Filing  
3/6/2014Robert W.A. SellersVPSell1,650$72.88$120,252.00View SEC Filing  
2/6/2014Michael MussallemCEOSell29,500$66.92$1,974,140.00View SEC Filing  
1/27/2014Michael BowlinDirectorSell1,092$68.65$74,965.80View SEC Filing  
1/9/2014Michael MussallemCEOSell29,500$67.04$1,977,680.00View SEC Filing  
1/6/2014Huimin WangVPSell5,600$67.14$375,984.00View SEC Filing  
12/11/2013Patrick VerguetVPSell10,000$62.34$623,400.00View SEC Filing  
12/5/2013Huimin WangVPSell4,650$64.65$300,622.50View SEC Filing  
12/4/2013Michael MussallemCEOSell29,500$64.90$1,914,550.00View SEC Filing  
10/9/2013Michael MussallemCEOSell29,500$72.63$2,142,585.00View SEC Filing  
10/4/2013Huimin WangVPSell4,850$72.19$350,121.50View SEC Filing  
9/12/2013Michael MussallemCEOSell29,500$71.82$2,118,690.00View SEC Filing  
9/5/2013Huimin WangVPSell4,850$71.24$345,514.00View SEC Filing  
8/8/2013Michael MussallemCEOSell29,500$72.28$2,132,260.00View SEC Filing  
8/5/2013Huimin WangVPSell4,850$72.30$350,655.00View SEC Filing  
8/1/2013Patrick VerguetVPSell20,000$73.15$1,463,000.00View SEC Filing  
7/10/2013Michael A MussallemCEOSell29,500$65.60$1,935,200.00View SEC Filing  
7/5/2013Huimin WangVPSell4,850$65.69$318,596.50View SEC Filing  
6/6/2013Michael A MussallemCEOSell29,500$66.25$1,954,375.00View SEC Filing  
6/5/2013Huimin WangVPSell4,850$65.11$315,783.50View SEC Filing  
5/13/2013Paul C RedmondVPSell5,000$67.35$336,750.00View SEC Filing  
5/8/2013Michael A MussallemCEOSell29,200$64.24$1,875,808.00View SEC Filing  
5/7/2013Thomas M AbateCFOSell15,000$63.75$956,250.00View SEC Filing  
5/3/2013Schack Wesley W VonDirectorBuy1,000$64.00$64,000.00View SEC Filing  
5/1/2013David E I PyottDirectorBuy3,000$62.95$188,850.00View SEC Filing  
5/1/2013John H Kehl JrVPSell12,500$62.72$784,000.00View SEC Filing  
4/26/2013Schack Wesley W VonDirectorBuy2,000$64.95$129,900.00View SEC Filing  
4/10/2013Michael A MussallemCEOSell35,000$83.37$2,917,950.00View SEC Filing  
3/13/2013John H Kehl JrVPSell12,500$87.75$1,096,875.00View SEC Filing  
10/5/2012Huimin WangVPSell6,250$109.88$686,750.00View SEC Filing  
10/4/2012Donald E Bobo JrVPSell11,530$110.14$1,269,914.20View SEC Filing  
8/9/2012Michael A MussallemCEOSell35,000$98.69$3,454,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Edwards Lifesciences Corporation (NYSE:EW)
Latest Headlines for Edwards Lifesciences Corporation (NYSE:EW)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Expect Edwards Lifesciences Corporation (EW) Will Announce Earnings of $0.87 Per Share
www.americanbankingnews.com - August 20 at 2:28 PM
finance.yahoo.com logo4 Stocks to Buy as Q2 Earnings Season Nears Close
finance.yahoo.com - August 18 at 11:27 PM
nasdaq.com logoAccuray's Radixact Now Used by Boise Summit Cancer Center - Nasdaq
www.nasdaq.com - August 18 at 6:24 PM
finance.yahoo.com logoHere's Why Investors Should Buy Edwards Lifesciences Now - Yahoo Finance
finance.yahoo.com - August 18 at 5:51 AM
finance.yahoo.com logoIs Edwards Lifesciences Corporation (EW) a Great Growth Stock?
finance.yahoo.com - August 17 at 7:47 PM
finance.yahoo.com logoHere's Why You Should Invest in IDEXX Laboratories (IDXX) Now
finance.yahoo.com - August 17 at 7:47 PM
finance.yahoo.com logoWalgreens' (WBA) Research Website to Add Value in Healthcare
finance.yahoo.com - August 17 at 7:47 PM
finance.yahoo.com logoInvacare (IVC) Introduces TDX SP2 Power Wheelchair Globally
finance.yahoo.com - August 16 at 6:35 PM
finance.yahoo.com logoMcKesson Banks on Distribution Business Amid Pricing Woes
finance.yahoo.com - August 16 at 6:35 PM
seekingalpha.com logoEdwards Lifesciences Stock To Remain Strong Ahead Of Robust Revenue And New Product Launch
seekingalpha.com - August 15 at 7:09 PM
finance.yahoo.com logoETFs with exposure to Edwards Lifesciences Corp. : August 15, 2017
finance.yahoo.com - August 15 at 7:09 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
finance.yahoo.com - August 14 at 11:52 PM
nasdaq.com logoMyriad Genetics (MYGN) Grows on Higher Cancer Test Volumes - Nasdaq
www.nasdaq.com - August 14 at 6:51 PM
nasdaq.com logoSTERIS (STE) Banks on Organic Growth, Competition Intense - Nasdaq
www.nasdaq.com - August 14 at 6:51 PM
finance.yahoo.com logoNevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat
finance.yahoo.com - August 10 at 7:48 PM
americanbankingnews.com logoMichael A. Mussallem Sells 32,900 Shares of Edwards Lifesciences Corporation (NYSE:EW) Stock
www.americanbankingnews.com - August 10 at 7:26 PM
finance.yahoo.com logoPenumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2
finance.yahoo.com - August 9 at 11:39 PM
finance.yahoo.com logoCVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed - Yahoo Finance
finance.yahoo.com - August 9 at 6:37 PM
finance.yahoo.com logoHaemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates - Yahoo Finance
finance.yahoo.com - August 9 at 4:18 AM
nasdaq.com logoCVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed - Nasdaq
www.nasdaq.com - August 8 at 11:16 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 8 at 8:40 PM
americanbankingnews.com logoInsider Selling: Edwards Lifesciences Corporation (EW) VP Sells 25,000 Shares of Stock
www.americanbankingnews.com - August 8 at 7:24 PM
finance.yahoo.com logoEnvision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss
finance.yahoo.com - August 8 at 6:13 PM
finance.yahoo.com logoEvolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top
finance.yahoo.com - August 8 at 6:13 PM
finance.yahoo.com logoLuminex (LMNX) Beats Earnings & Revenue Estimates in Q2
finance.yahoo.com - August 8 at 6:13 PM
finance.yahoo.com logoSurmodics (SRDX) Beats Earnings & Revenue Estimates in Q3
finance.yahoo.com - August 8 at 4:44 AM
nasdaq.com logoCardiovascular Systems Rides on Innovation Amid Several Woes - Nasdaq
www.nasdaq.com - August 7 at 6:41 PM
finance.yahoo.com logoCogentix (CGNT) Looks Good: Stock Moves Up 5.2% in Session
finance.yahoo.com - August 7 at 6:41 PM
seekingalpha.com logoEdwards Lifesciences Will Wow Investors With Stellar Performance In SAVR Segment In 2017 - Seeking Alpha
seekingalpha.com - August 6 at 3:54 AM
finance.yahoo.com logoIllumina (ILMN) Rides on New Products, Low Margin a Concern
finance.yahoo.com - August 4 at 6:47 PM
finance.yahoo.com logoInogen (INGN) Beats Earnings and Revenue Estimates in Q2
finance.yahoo.com - August 4 at 6:47 PM
finance.yahoo.com logoWright Medical Group (WMGI) Q2 Loss Narrower than Expected
finance.yahoo.com - August 4 at 6:47 PM
finance.yahoo.com logoPacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss
finance.yahoo.com - August 4 at 6:47 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) Expected to Announce Quarterly Sales of $834.53 Million
www.americanbankingnews.com - August 4 at 7:36 AM
nasdaq.com logoCardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top - Nasdaq
www.nasdaq.com - August 3 at 3:24 PM
nasdaq.com logoMasimo (MASI) Beats on Q2 Earnings and Revenues, Guides Up - Nasdaq
www.nasdaq.com - August 3 at 3:24 PM
finance.yahoo.com logoMasimo (MASI) Beats on Q2 Earnings and Revenues, Guides Up
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoEdwards Lifesciences Focuses on Expanding Market for TAVR Therapy in 2017
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoEdwards Lifesciences: Focused on Inspiris Resilia and Konect
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoCardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoFresenius Medical (FMS) Q2 Earnings Miss, FY17 View Intact
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoBecton, Dickinson (BDX) Beats on Q3 Earnings, Guidance Solid
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoAmerisourceBergen (ABC) Beats on Q3 Earnings, Revenues Lag
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoEdwards Lifesciences Focuses on Launch of SAPIEN 3 Ultra and CENTERA Valves
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoEdwards Lifesciences’ Mitral Regurgitation Segment
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoEdwards Lifesciences Focuses on Indication Expansion of SAPIEN 3 in 2017
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoHologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoCA Inc leading the CNBC IQ100
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoHeart-Felt Buys: 6 Cardiac Opportunities
finance.yahoo.com - August 3 at 3:24 PM
finance.yahoo.com logoTAVR Therapy Expected to Witness Solid Growth in Demand in 2017
finance.yahoo.com - August 3 at 12:26 AM

Social

Chart

Edwards Lifesciences Corporation (EW) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff